acitretin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	78	55079-83-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acitretin acitretinoin etretin neotigason soriatane isoacitretin isoetretin	An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. Molecular weight: 326.44 Formula: C21H26O3 CLOGP: 6.07 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -5.83 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acitretin
acitretinoin
etretin
neotigason
soriatane
isoacitretin
isoetretin

An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.

Molecular weight: 326.44
Formula: C21H26O3
CLOGP: 6.07
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.83
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
35	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	59 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Oct. 28, 1996	FDA	STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	813.23	21.00	332	7821	68668	50528303
Skin haemorrhage	180.48	21.00	60	8093	6858	50590113
Skin exfoliation	138.49	21.00	79	8074	33533	50563438
Psoriatic arthropathy	109.41	21.00	77	8076	46955	50550016
Neurologic neglect syndrome	82.70	21.00	23	8130	1435	50595536
Respiratory tract congestion	82.61	21.00	42	8111	14157	50582814
Carotid artery thrombosis	82.07	21.00	23	8130	1476	50595495
Sinus congestion	71.73	21.00	38	8115	13933	50583038
Sneezing	71.54	21.00	38	8115	14006	50582965
Cutaneous T-cell lymphoma	62.90	21.00	18	8135	1246	50595725
Adjustment disorder	62.73	21.00	20	8133	1999	50594972
Sinus disorder	61.86	21.00	38	8115	18420	50578551
Drug ineffective	60.88	21.00	276	7877	819057	49777914
Personality disorder	58.16	21.00	23	8130	4301	50592670
Rhinorrhoea	57.38	21.00	55	8098	51528	50545443
Skin plaque	56.04	21.00	25	8128	6303	50590668
Infected dermal cyst	54.43	21.00	13	8140	441	50596530
Rash pustular	52.31	21.00	24	8129	6457	50590514
Rhesus antigen positive	51.41	21.00	10	8143	124	50596847
Pruritus	51.02	21.00	129	8024	283439	50313532
Skin lesion	49.12	21.00	38	8115	26689	50570282
Erythema	49.08	21.00	86	8067	146328	50450643
Sensory loss	48.26	21.00	24	8129	7714	50589257
Oral lichen planus	47.26	21.00	12	8141	526	50596445
Hemiplegia	46.35	21.00	23	8130	7358	50589613
Dry skin	46.05	21.00	45	8108	43146	50553825
Affect lability	44.84	21.00	24	8129	8974	50587997
Motor dysfunction	44.51	21.00	23	8130	8008	50588963
Erythrodermic psoriasis	40.87	21.00	12	8141	909	50596062
Wrong technique in device usage process	39.76	21.00	15	8138	2471	50594500
Weaning failure	37.46	21.00	9	8144	313	50596658
Coordination abnormal	36.75	21.00	23	8130	11511	50585460
Guttate psoriasis	36.32	21.00	9	8144	357	50596614
Burning sensation	35.31	21.00	40	8113	45406	50551565
Skin fissures	34.65	21.00	20	8133	8648	50588323
Blood immunoglobulin M decreased	34.65	21.00	10	8143	713	50596258
Squamous cell carcinoma	34.02	21.00	19	8134	7720	50589251
Influenza	33.14	21.00	55	8098	89483	50507488
Blood albumin increased	32.77	21.00	10	8143	865	50596106
Lichen planus	31.86	21.00	12	8141	1967	50595004
Immunoglobulins decreased	31.35	21.00	10	8143	1000	50595971
Cystitis	30.90	21.00	37	8116	44527	50552444
Eating disorder	30.71	21.00	23	8130	15386	50581585
Muscle spasticity	30.63	21.00	24	8129	17160	50579811
Type IIb hyperlipidaemia	28.95	21.00	5	8148	30	50596941
Inflammatory bowel disease	28.54	21.00	13	8140	3437	50593534
Oesophageal stenosis	27.59	21.00	12	8141	2846	50594125
Hemiparesis	27.39	21.00	24	8129	20024	50576947
Increased bronchial secretion	27.08	21.00	10	8143	1552	50595419
Pustular psoriasis	26.77	21.00	13	8140	3968	50593003
Tongue ulceration	26.73	21.00	12	8141	3068	50593903
Inappropriate schedule of product administration	26.40	21.00	44	8109	71787	50525184
Injection site bruising	26.27	21.00	31	8122	36737	50560234
Sunburn	26.21	21.00	11	8142	2392	50594579
Face oedema	25.67	21.00	22	8131	17817	50579154
Onychalgia	25.21	21.00	8	8145	787	50596184
Influenza like illness	24.97	21.00	38	8115	57421	50539550
Blood immunoglobulin G decreased	24.75	21.00	10	8143	1975	50594996
Tanning	24.70	21.00	5	8148	77	50596894
Toxicity to various agents	23.99	21.00	3	8150	212496	50384475
Oesophageal ulcer	23.90	21.00	12	8141	3933	50593038
Skin infection	23.73	21.00	18	8135	12273	50584698
Mean cell haemoglobin increased	23.67	21.00	10	8143	2210	50594761
Skin atrophy	23.07	21.00	12	8141	4233	50592738
Pregnancy of partner	22.38	21.00	4	8149	30	50596941
Retroperitoneal abscess	22.21	21.00	5	8148	130	50596841
Aphasia	21.99	21.00	25	8128	28469	50568502
Plantar fasciitis	21.04	21.00	10	8143	2911	50594060
Rickets	21.00	21.00	4	8149	44	50596927

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	703.90	22.35	253	5283	31974	29537017
Vein rupture	195.27	22.35	41	5495	652	29568339
Drug ineffective	187.05	22.35	279	5257	362891	29206100
Skin plaque	164.06	22.35	50	5486	3712	29565279
Venous injury	110.50	22.35	22	5514	264	29568727
Injection site haemorrhage	104.40	22.35	44	5492	8342	29560649
Injection site papule	85.30	22.35	18	5518	293	29568698
Erythrodermic psoriasis	83.00	22.35	21	5515	779	29568212
Dermatitis exfoliative generalised	82.87	22.35	28	5508	2888	29566103
Injection site swelling	80.57	22.35	38	5498	9379	29559612
Inappropriate schedule of product administration	79.28	22.35	66	5470	44406	29524585
Cutaneous T-cell lymphoma	77.50	22.35	22	5514	1271	29567720
Squamous cell carcinoma	60.05	22.35	32	5504	10219	29558772
Psoriatic arthropathy	59.44	22.35	36	5500	14655	29554336
Skin erosion	58.66	22.35	19	5517	1717	29567274
Hypercholesterolaemia	55.20	22.35	27	5509	7211	29561780
Granuloma annulare	55.01	22.35	11	5525	135	29568856
Squamous cell carcinoma of skin	51.06	22.35	28	5508	9458	29559533
Pain in extremity	47.90	22.35	79	5457	110354	29458637
Phototherapy	47.81	22.35	8	5528	32	29568959
Pain of skin	47.40	22.35	20	5516	3795	29565196
Myalgia	44.97	22.35	62	5474	73957	29495034
Therapeutic product effect incomplete	43.98	22.35	45	5491	39260	29529731
Pruritus	43.33	22.35	78	5458	116771	29452220
Muscular weakness	40.76	22.35	54	5482	61998	29506993
Keratoacanthoma	40.17	22.35	11	5525	556	29568435
Basal cell carcinoma	38.46	22.35	29	5507	16881	29552110
Pityriasis rubra pilaris	37.39	22.35	7	5529	59	29568932
Induration	35.44	22.35	11	5525	865	29568126
Malignant melanoma stage I	35.00	22.35	7	5529	86	29568905
Skin exfoliation	34.98	22.35	31	5505	22614	29546377
Botryomycosis	34.13	22.35	6	5530	34	29568957
Macule	33.84	22.35	11	5525	1005	29567986
Insomnia	33.83	22.35	60	5476	88701	29480290
Hyperkeratosis	33.62	22.35	15	5521	3254	29565737
Neuroendocrine tumour of the lung metastatic	33.52	22.35	7	5529	108	29568883
Retinal disorder	31.01	22.35	10	5526	890	29568101
Myasthenia gravis	30.94	22.35	14	5522	3137	29565854
Decreased immune responsiveness	30.09	22.35	11	5525	1428	29567563
Skin injury	28.83	22.35	10	5526	1114	29567877
Drug intolerance	28.56	22.35	40	5496	48339	29520652
Erythema	27.38	22.35	50	5486	75556	29493435
Type 2 diabetes mellitus	25.91	22.35	21	5515	13560	29555431
Gastrointestinal tube insertion	24.98	22.35	9	5527	1120	29567871
Hepatic cirrhosis	24.78	22.35	21	5515	14423	29554568
Hidradenitis	24.64	22.35	8	5528	728	29568263
Hypereosinophilic syndrome	24.24	22.35	6	5530	203	29568788
Skin lesion	23.97	22.35	23	5513	18549	29550442
Emotional distress	23.43	22.35	20	5516	13875	29555116
Angioplasty	22.71	22.35	8	5528	933	29568058
Cutaneous symptom	22.63	22.35	6	5530	268	29568723
Toxicity to various agents	22.44	22.35	3	5533	173658	29395333

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	1283.92	19.20	492	12063	71211	64414966
Drug ineffective	209.95	19.20	485	12070	839762	63646415
Skin haemorrhage	182.15	19.20	67	12488	8518	64477659
Skin plaque	161.42	19.20	62	12493	8878	64477299
Vein rupture	160.94	19.20	41	12514	1502	64484675
Skin exfoliation	140.73	19.20	95	12460	44790	64441387
Cutaneous T-cell lymphoma	126.02	19.20	37	12518	2315	64483862
Psoriatic arthropathy	113.24	19.20	82	12473	43199	64442978
Squamous cell carcinoma	98.73	19.20	50	12505	13819	64472358
Inappropriate schedule of product administration	95.13	19.20	103	12452	92183	64393994
Injection site haemorrhage	94.79	19.20	59	12496	24219	64461958
Erythrodermic psoriasis	94.18	19.20	27	12528	1552	64484625
Venous injury	93.31	19.20	22	12533	580	64485597
Dermatitis exfoliative generalised	89.13	19.20	36	12519	5880	64480297
Pruritus	78.92	19.20	182	12373	312218	64173959
Neurologic neglect syndrome	76.03	19.20	23	12532	1595	64484582
Carotid artery thrombosis	73.67	19.20	23	12532	1772	64484405
Skin lesion	71.01	19.20	58	12497	36424	64449753
Respiratory tract congestion	70.04	19.20	42	12513	16123	64470054
Injection site papule	66.93	19.20	18	12537	816	64485361
Sneezing	61.90	19.20	38	12517	15213	64470964
Sinus congestion	61.47	19.20	38	12517	15401	64470776
Sinus disorder	60.76	19.20	39	12516	16869	64469308
Erythema	56.24	19.20	117	12438	186953	64299224
Keratoacanthoma	56.04	19.20	16	12539	906	64485271
Toxicity to various agents	55.45	19.20	4	12551	363509	64122668
Adjustment disorder	53.00	19.20	20	12535	2725	64483452
Personality disorder	52.05	19.20	23	12532	4688	64481489
Rhinorrhoea	49.99	19.20	60	12495	59909	64426268
Rhesus antigen positive	49.52	19.20	10	12545	124	64486053
Skin erosion	46.32	19.20	20	12535	3856	64482321
Therapeutic product effect incomplete	45.19	19.20	76	12479	103406	64382771
Pain of skin	44.48	19.20	26	12529	9521	64476656
Squamous cell carcinoma of skin	44.18	19.20	28	12527	11848	64474329
Pityriasis rubra pilaris	42.15	19.20	8	12547	70	64486107
Pain in extremity	42.00	19.20	142	12413	302943	64183234
Phototherapy	41.55	19.20	7	12548	28	64486149
Hyperkeratosis	41.54	19.20	22	12533	6659	64479518
Affect lability	40.61	19.20	24	12531	8966	64477211
Infected dermal cyst	40.42	19.20	12	12543	780	64485397
Sensory loss	40.40	19.20	25	12530	10144	64476033
Onychalgia	40.34	19.20	12	12543	785	64485392
Granuloma annulare	40.31	19.20	11	12544	527	64485650
Skin fissures	40.09	19.20	25	12530	10281	64475896
Pustular psoriasis	38.55	19.20	18	12537	4165	64482012
Myalgia	38.38	19.20	91	12464	158526	64327651
Oral lichen planus	37.74	19.20	11	12544	670	64485507
Hypercholesterolaemia	37.63	19.20	28	12527	15345	64470832
Dry skin	37.51	19.20	48	12507	51113	64435064
Injection site swelling	37.15	19.20	43	12512	41310	64444867
Muscular weakness	36.32	19.20	78	12477	127260	64358917
Rash pustular	36.01	19.20	23	12532	9862	64476315
Motor dysfunction	35.43	19.20	24	12531	11349	64474828
Induration	35.33	19.20	13	12542	1651	64484526
Guttate psoriasis	33.81	19.20	9	12546	392	64485785
Influenza	33.58	19.20	68	12487	106463	64379714
Neuroendocrine tumour of the lung metastatic	33.18	19.20	7	12548	109	64486068
Malignant melanoma stage I	32.44	19.20	7	12548	122	64486055
Dyslipidaemia	32.42	19.20	21	12534	9221	64476956
Wrong technique in device usage process	31.61	19.20	14	12541	2868	64483309
Hemiplegia	30.68	19.20	23	12532	12745	64473432
Immunoglobulins decreased	30.60	19.20	11	12544	1307	64484870
Macule	30.58	19.20	13	12542	2413	64483764
Acute kidney injury	30.06	19.20	26	12529	449214	64036963
Weaning failure	29.84	19.20	9	12546	617	64485560
Blood immunoglobulin M decreased	29.75	19.20	10	12545	974	64485203
Cystitis	28.12	19.20	38	12517	42637	64443540
Type IIb hyperlipidaemia	28	19.20	5	12550	30	64486147
Coordination abnormal	27.46	19.20	23	12532	14941	64471236
Muscle spasticity	27.29	19.20	24	12531	16645	64469532
Skin atrophy	27.24	19.20	15	12540	4905	64481272
Skin disorder	26.92	19.20	30	12525	27650	64458527
Burning sensation	26.51	19.20	40	12515	49624	64436553
Blood albumin increased	26.51	19.20	10	12545	1361	64484816
Inflammatory bowel disease	25.57	19.20	14	12541	4524	64481653
Rebound psoriasis	25.45	19.20	6	12549	158	64486019
Eating disorder	25.15	19.20	23	12532	16782	64469395
Insomnia	25.02	19.20	90	12465	197746	64288431
Botryomycosis	24.99	19.20	5	12550	59	64486118
Neutropenia	24.60	19.20	8	12547	239616	64246561
Lichen planus	24.54	19.20	11	12544	2317	64483860
Cutaneous symptom	23.91	19.20	7	12548	433	64485744
Tanning	23.88	19.20	5	12550	75	64486102
Death	23.56	19.20	36	12519	482669	64003508
Hypotension	23.18	19.20	24	12531	380950	64105227
Basal cell carcinoma	22.70	19.20	29	12526	30809	64455368
Psoriasis area severity index increased	22.33	19.20	5	12550	104	64486073
Nasopharyngitis	22.12	19.20	86	12469	195987	64290190
Arthritis	21.25	19.20	49	12506	83765	64402412
Sunburn	20.79	19.20	11	12544	3321	64482856
Cellulitis	20.78	19.20	52	12503	93605	64392572
Somnolence	20.55	19.20	7	12548	203638	64282539
Injection site bruising	20.42	19.20	30	12525	36343	64449834
Diffuse idiopathic skeletal hyperostosis	20.42	19.20	4	12551	42	64486135
Blood immunoglobulin G decreased	20.05	19.20	10	12545	2673	64483504
Myasthenia gravis	20.03	19.20	13	12542	5725	64480452
Tongue ulceration	19.92	19.20	11	12544	3615	64482562
Anaemia	19.68	19.20	27	12528	378653	64107524
Plantar fasciitis	19.58	19.20	10	12545	2810	64483367
Increased bronchial secretion	19.50	19.20	10	12545	2832	64483345
Skin infection	19.48	19.20	19	12536	15018	64471159
Oesophageal stenosis	19.35	19.20	11	12544	3823	64482354
Dehydration	19.33	19.20	9	12546	216754	64269423

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D05BB02	DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis
FDA CS	M0018962	Retinoids
FDA EPC	N0000175607	Retinoid
CHEBI has role	CHEBI:50176	keratolytic drugs
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Severe Recalcitrant Psoriasis	indication
Lichen planus	off-label use	4776004	DOID:9201
Keratosis follicularis	off-label use	48611009	DOID:2734
Lamellar ichthyosis	off-label use	205550003
Ichthyosiform erythroderma	off-label use	268282005
Primary cutaneous T-cell lymphoma	off-label use	400122007
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Depressive disorder	contraindication	35489007
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Night blindness	contraindication	65194006	DOID:8499
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Diabetes mellitus	contraindication	73211009	DOID:9351
Premature epiphyseal closure	contraindication	89493005
Liver function tests abnormal	contraindication	166603001
Hypoalphalipoproteinemia	contraindication	190785000
Acute pancreatitis	contraindication	197456007	DOID:2913
Hypertrophy of bone	contraindication	203514008	DOID:205
Drug-induced hepatitis	contraindication	235876009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Psychiatric Disturbance	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST			WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST			CHEMBL	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	4.74	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.71	CHEMBL

External reference:

ID	Source
4021061	VUID
N0000148524	NUI
D02754	KEGG_DRUG
16818	RXNORM
C0050559	UMLSCUI
CHEBI:50173	CHEBI
CHEMBL1131	ChEMBL_ID
DB00459	DRUGBANK_ID
D017255	MESH_DESCRIPTOR_UI
5284513	PUBCHEM_CID
7598	IUPHAR_LIGAND_ID
5530	INN_ID
69427-46-9	SECONDARY_CAS_RN
LCH760E9T7	UNII
11379	MMSL
117161	MMSL
4128	MMSL
d03836	MMSL
004121	NDDF
4021061	VANDF
108914001	SNOMEDCT_US
386938006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1750	CAPSULE	10 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1751	CAPSULE	17.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1752	CAPSULE	22.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1753	CAPSULE	25 mg	ORAL	ANDA	17 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0090	CAPSULE	10 mg	ORAL	NDA	27 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0091	CAPSULE	25 mg	ORAL	NDA	27 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-086	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-087	CAPSULE	17.50 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-088	CAPSULE	25 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-080	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-081	CAPSULE	17.50 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-083	CAPSULE	25 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	66993-894	CAPSULE	10 mg	ORAL	NDA authorized generic	16 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	66993-896	CAPSULE	25 mg	ORAL	NDA authorized generic	16 sections